Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Antiviral Therapy|May 17, 2007
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne-Genevieve Marcelin, Philippe Flandre, Carmen de Mendoza, et al.
The Journal of Antimicrobial Chemotherapy|February 18, 2009
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsIsabelle Malet, Olivier Delelis, Cathia Soulie, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2015
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencingEve Todesco, Christophe Rodriguez, Laurence Morand-Joubert, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2010
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulié, Slim Fourati, Sidonie Lambert-Niclot, et al.
The Journal of Infection|August 1, 2006
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patientsIsabelle Malet, Bénédicte Roquebert, Cécile Dalban, et al.
Journal of Medical Virology|December 21, 2006
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez, Jade Ghosn, Gilles Peytavin, et al.
AIDS (London, England)|March 13, 2009
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in FranceMarie-Laure Chaix, Diane Descamps, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practiceMarc Wirden, Eve Todesco, Marc-Antoine Valantin, et al.
Journal of Clinical Microbiology|June 7, 2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden, Anne Simon, Luminita Schneider, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2008
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot, Philippe Flandre, Isabelle Malet, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Antiviral Therapy|May 17, 2007
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne-Genevieve Marcelin, Philippe Flandre, Carmen de Mendoza, et al.
The Journal of Antimicrobial Chemotherapy|February 18, 2009
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsIsabelle Malet, Olivier Delelis, Cathia Soulie, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2015
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencingEve Todesco, Christophe Rodriguez, Laurence Morand-Joubert, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2010
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulié, Slim Fourati, Sidonie Lambert-Niclot, et al.
The Journal of Infection|August 1, 2006
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patientsIsabelle Malet, Bénédicte Roquebert, Cécile Dalban, et al.
Journal of Medical Virology|December 21, 2006
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez, Jade Ghosn, Gilles Peytavin, et al.
AIDS (London, England)|March 13, 2009
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in FranceMarie-Laure Chaix, Diane Descamps, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practiceMarc Wirden, Eve Todesco, Marc-Antoine Valantin, et al.
Journal of Clinical Microbiology|June 7, 2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden, Anne Simon, Luminita Schneider, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2008
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot, Philippe Flandre, Isabelle Malet, et al.
Pageof 10